The stock of Biocryst Pharmaceuticals Inc (BCRX) has gone up by 7.52% for the week, with a 2.96% rise in the past month and a -0.62% drop in the past quarter. The volatility ratio for the week is 4.66%, and the volatility levels for the past 30 days are 5.33% for BCRX. The simple moving average for the last 20 days is 4.56% for BCRX’s stock, with a simple moving average of 13.65% for the last 200 days.
Is It Worth Investing in Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Right Now?
The 36-month beta value for BCRX is also noteworthy at 1.74. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 6 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for BCRX is 195.42M, and at present, short sellers hold a 8.04% of that float. The average trading volume of BCRX on January 28, 2025 was 2.23M shares.
BCRX) stock’s latest price update
The stock of Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) has increased by 4.84 when compared to last closing price of 7.64.Despite this, the company has seen a gain of 7.52% in its stock price over the last five trading days. globenewswire.com reported 2025-01-10 that —ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB ® ) expected to be between $540-$560 million in 2025— —Company achieved operating profit in 2024 (not including stock-based compensation) and expects to approach quarterly EPS profitability/positive cash flow in 2H 2025— —New drug application planned in 2025 for ORLADEYO granules in children up to age 12; will address significant unmet need— —Pipeline advancing into patients with Netherton syndrome (BCX17725) and diabetic macular edema (avoralstat) in 2025— RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO® (berotralstat) net revenue and total revenue for the fourth quarter and full year 2024.
Analysts’ Opinion of BCRX
Many brokerage firms have already submitted their reports for BCRX stocks, with JP Morgan repeating the rating for BCRX by listing it as a “Overweight.” The predicted price for BCRX in the upcoming period, according to JP Morgan is $10 based on the research report published on November 20, 2023 of the previous year 2023.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see BCRX reach a price target of $10, previously predicting the price at $9. The rating they have provided for BCRX stocks is “Outperform” according to the report published on September 18th, 2023.
Jefferies gave a rating of “Buy” to BCRX, setting the target price at $11 in the report published on August 04th of the previous year.
BCRX Trading at 5.89% from the 50-Day Moving Average
After a stumble in the market that brought BCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.80% of loss for the given period.
Volatility was left at 5.33%, however, over the last 30 days, the volatility rate increased by 4.66%, as shares surge +4.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.20% lower at present.
During the last 5 trading sessions, BCRX rose by +7.52%, which changed the moving average for the period of 200-days by +66.88% in comparison to the 20-day moving average, which settled at $7.66. In addition, Biocryst Pharmaceuticals Inc saw 6.52% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCRX starting from Hutson Nancy J, who sale 7,000 shares at the price of $7.54 back on Dec 13 ’24. After this action, Hutson Nancy J now owns 86,638 shares of Biocryst Pharmaceuticals Inc, valued at $52,780 using the latest closing price.
Hutson Nancy J, the Director of Biocryst Pharmaceuticals Inc, proposed sale 7,000 shares at $7.51 during a trade that took place back on Dec 13 ’24, which means that Hutson Nancy J is holding shares at $52,584 based on the most recent closing price.
Stock Fundamentals for BCRX
Current profitability levels for the company are sitting at:
- -0.1 for the present operating margin
- 0.98 for the gross margin
The net margin for Biocryst Pharmaceuticals Inc stands at -0.3. The total capital return value is set at -0.12.
Based on Biocryst Pharmaceuticals Inc (BCRX), the company’s capital structure generated 2.38 points at debt to capital in total, while cash flow to debt ratio is standing at -0.07. The debt to equity ratio resting at -1.73. The interest coverage ratio of the stock is -0.41.
Currently, EBITDA for the company is -116.33 million with net debt to EBITDA at -25.82. When we switch over and look at the enterprise to sales, we see a ratio of 5.75. The receivables turnover for the company is 5.69for trailing twelve months and the total asset turnover is 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.78.
Conclusion
In summary, Biocryst Pharmaceuticals Inc (BCRX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
